No Prescription |
 |
 | ||
|
Dilantin Paed Susp Generic Phenytoin |
|
| ||
No Prescription » Prescription Drugs 6 » Dilantin Paed Susp Generic Phenytoin Phenytoin is used to prevent and control seizures (also called an anticonvulsant or antiepileptic drug). It works by reducing the spread of seizure activity in the brain.Indication:Dilantin is indicated for the control of grand mal and psychomotor seizures. Dilantin will prevent or effectively decrease the incidence and severity of convulsive seizures in a high percentage of cases with patients exhibiting little tendency to become resistant to its action. Besides its effectiveness in controlling seizures Dilantin frequently improves the mental condition and outlook of epileptic patients and there is also increasing evidence that Dilantin is valuable in the prevention of seizures occurring during or after neurosurgery and in the treatment of certain cardiac arrythmias. Phenytoin serum level determinations may be necessary for optimal dosage adjustments (see Dosage and Administration).Dosage and Administration:PaediatricInitiate therapy with 5 mg/kg/day in 2 to 3 equally divided doses not to exceed 300 mg daily. A recommended daily maintenance dosage is usually 4 to 8 mg/kg. Children over 6 years may require the minimum adult dose (300 mg/day).Paediatric dosage forms available include Dilantin Chewable Infatabs and Dilantin Paediatric Suspension. Buy Dilantin Paed Susp Generic Phenytoin and other Prescription Drugs 6 products online at Medstore. Buy Online at Medstore - Click Here!
About Dilantin Paed Susp Generic Phenytoin: Product Type: Prescription Drugs 6 Dilantin Paed Susp ( Generic Phenytoin ) Dilantin Paed Susp (Generic Phenytoin) Generic Phenytoin 30mg/5mL 500mL 1500mL(3 x 500mL) Generic Phenytoin Dilantin Paed Susp
View more Prescription Drugs 6 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
